Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Votrient - NPS MedicineWise
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research
The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
820-Renal cell metastatic pAZOPanib | eviQ
Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer | SpringerLink
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer | Future Oncology
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update - ScienceDirect
Survival distributions for progression-free (PFS) and overall survival... | Download Scientific Diagram
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma | PNAS
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | Signal Transduction and Targeted Therapy
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
